192
Participants
Start Date
November 10, 2020
Primary Completion Date
July 11, 2024
Study Completion Date
December 31, 2026
Ami-LC-MD
Participants will receive amivantamab admixed with rHuPH20 SC infusion.
Ami-LC
Participants will receive amivantamab SC infusion.
Ami-HC
Participants will receive amivantamab SC infusion.
Ami-HC-CF
Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
Lazertinib
Participants will receive lazertinib orally as a film-coated tablet.
Langone Health at NYC University, NYU School of Medicine, New York
Seoul National University Bundang Hospital, Seongnam-si
Chungbuk National University Hospital, Cheongju-si
Sarah Cannon Research Institute, Nashville
Community Health Network, Indianapolis
Cedars Sinai Medical Center, West Hollywood
Providence Portland Medical Center, Portland
University Health Network, Toronto
Severance Hospital Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
The Christie Nhs Foundation Trust, Manchester
Royal Marsden Hospital, Sutton
Janssen Research & Development, LLC
INDUSTRY